BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 36519233)

  • 21. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
    Passamonti F
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S25-7. PubMed ID: 22035744
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.
    Rumi E; Cazzola M
    Blood; 2017 Feb; 129(6):680-692. PubMed ID: 28028026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
    Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
    Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A
    Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High Risk Janus Kinase 2 V617F Allele Burden in a Seven-Year Cohort of Patients with Myeloproliferative Neoplasms.
    Chatambudza M; Skhosana L; Ketseoglou I; Wiggill T
    Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria.
    Yassin MA; Taher A; Mathews V; Hou HA; Shamsi T; Tuğlular TF; Xiao Z; Kim SJ; Depei W; Li J; Rippin G; Sadek I; Siddiqui A; Wong RS
    Cancer Med; 2020 Jul; 9(13):4512-4526. PubMed ID: 32351024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.
    Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M
    Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions.
    Strati P; Bose P; Lyle L; Gaw K; Zhou L; Pierce SA; Huynh-Lu J; Hirsch-Ginsberg CF; Bueso-Mendoza DE; Bueso-Ramos CE; Verstovsek S
    Ann Hematol; 2017 May; 96(5):733-738. PubMed ID: 28247057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
    Mesa R; Jamieson C; Bhatia R; Deininger MW; Gerds AT; Gojo I; Gotlib J; Gundabolu K; Hobbs G; Klisovic RB; Kropf P; Mohan SR; Oh S; Padron E; Podoltsev N; Pollyea DA; Rampal R; Rein LA; Scott B; Snyder DS; Stein BL; Verstovsek S; Wadleigh M; Wang ES; Bergman MA; Gregory KM; Sundar H
    J Natl Compr Canc Netw; 2016 Dec; 14(12):1572-1611. PubMed ID: 27956542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient-Reported Outcomes in Young Adults with Myeloproliferative Neoplasms.
    Bao M; Zhang M; Shi H; Liu X; Duan M; Zhuang J; Du X; Qin L; Hui W; Liang R; Wang M; Chen Y; Li D; Yang W; Tang G; Zhang W; Kuang X; Su W; Han Y; Chen L; Xu J; Liu Z; Huang J; Zhao C; Tong H; Hu J; Chen C; Chen X; Xiao Z; Jiang Q
    Acta Haematol; 2023; 146(4):293-306. PubMed ID: 36812897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis.
    Masarova L; Verstovsek S
    Clin Adv Hematol Oncol; 2019 May; 17(5):299-307. PubMed ID: 31188809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum procalcitonin in Philadelphia-negative myeloproliferative neoplasms.
    Krečak I; Peran N; Lapić I; Gverić-Krečak V; Krečak F; Rončević P; Duraković N
    Wien Klin Wochenschr; 2021 Jan; 133(1-2):62-64. PubMed ID: 32300883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pediatric Myeloproliferative Neoplasms.
    El-Sharkawy F; Margolskee E
    Clin Lab Med; 2021 Sep; 41(3):529-540. PubMed ID: 34304780
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: a Review of the Recent Literature.
    Zhou A; Afzal A; Oh ST
    Curr Hematol Malig Rep; 2017 Oct; 12(5):397-405. PubMed ID: 28948488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).
    Michiels JJ; Thiele J
    Int J Hematol; 2002 Aug; 76(2):133-45. PubMed ID: 12215011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
    Brière J
    Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.